Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism.
about
Opioid antagonists for alcohol dependenceA blocker of N- and T-type voltage-gated calcium channels attenuates ethanol-induced intoxication, place preference, self-administration, and reinstatementChronic alcohol neuroadaptation and stress contribute to susceptibility for alcohol craving and relapseConceptual framework for the etiology of alcoholism: a "kindling"/stress hypothesis.Functional impact of a single-nucleotide polymorphism in the OPRD1 promoter region.Does naltrexone affect craving in abstinent opioid-dependent patients?Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study.μ-Opioid receptor gene (OPRM1) polymorphism A118G: lack of association in Finnish populations with alcohol dependence or alcohol consumptionEffect of surfactants and pH on naltrexone (NTX) permeation across buccal mucosa.Differential effects of naltrexone on cardiac, subjective and behavioural reactions to acute ethanol intoxicationInteraction between family history of alcoholism and Locus of Control in the opioid regulation of impulsive responding under the influence of alcohol.Critical thoughts on current rodent models for evaluating potential treatments of alcohol addiction and withdrawalPrazosin + Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in P Rats with a Protracted History of Extensive Voluntary Alcohol Drinking, Dependence, and Multiple Withdrawals.Self-administration of cannabinoids by experimental animals and human marijuana smokers.Pharmacotherapy for alcohol dependence: anticraving medications for relapse prevention.Modulation of high alcohol drinking in the inbred Fawn-Hooded (FH/Wjd) rat strain: implications for treatment.Preclinical and clinical pharmacology of alcohol dependence.Role of exercise in the treatment of alcohol use disorders.Prescription of topiramate to treat alcohol use disorders in the Veterans Health AdministrationEffect of naltrexone during extinction of alcohol-reinforced responding and during repeated cue-conditioned reinstatement sessions in a cue exposure style treatment.Attenuation of the stimulant response to ethanol is associated with enhanced ataxia for a GABA, but not a GABA, receptor agonist.Acamprosate: a new tool in the battle against alcohol dependence.Now or Later? An fMRI study of the effects of endogenous opioid blockade on a decision-making network.The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders.Emerging drugs to treat alcoholism.Evolving therapeutic indications for N-type calcium channel blockers: from chronic pain to alcohol abuse.Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status.Effects of naltrexone on alcohol self-administration and craving: meta-analysis of human laboratory studies.Breaking the addictive cycle of the system: improving US criminal justice practices to address substance use disorders.Sodium oxybate plus nalmefene for the treatment of alcohol use disorder: A case series.Topiramate reduces the harm of excessive drinking: implications for public health and primary care.Naltrexone efficacy in treating alcohol-use disorder in individuals with comorbid psychosis: a systematic reviewEffects of naltrexone and acamprosate on alcohol-induced NGFI-A expression in mouse brain.Pharmacological approaches to the treatment of excessive drinking and alcohol dependence.Endogenous opioid blockade and impulsive responding in alcoholics and healthy controls.Downregulation of mu opioid receptor by RNA interference in the ventral tegmental area reduces ethanol consumption in mice.Alleviating waiting impulsivity and perseverative responding by μ-opioid receptor antagonism in two inbred mouse strains.Improved effect of the combination naltrexone/D-penicillamine in the prevention of alcohol relapse-like drinking in rats.Naltrexone treatment produces dose-related effects on food and water intake but daily alcohol consumption is not affected.
P2860
Q24235797-7BFDFB33-F251-467E-91C5-2BEEB61DAD23Q24613295-CA579AAA-1FCD-43FB-88DE-055E1B3A57FDQ24633835-6A6F2A9E-6F4E-4A4B-ABDF-CF31B5CA9004Q30479081-0CA4814A-26A3-46C7-96B6-07B14EDE1F14Q33875900-0076AFE0-7A87-4B5C-88AB-5E474724F6FCQ34004211-D391DC5D-61C5-413E-BD9C-ECB372BA6F7DQ34306652-DA3CF9A5-6F9E-4D39-9EC4-5CBE1D2F4741Q34711313-AB6033F4-B0CC-4BC7-9D3A-3F42ACF6B989Q34975089-7FAD425F-8885-4A2D-B46D-798E98F96376Q35012619-95E5E85D-CC35-48ED-B8B9-C62D36548F7EQ35129315-3B9D00AA-5005-46C9-BC8A-F3B8AD70341BQ35172775-BB48273C-94B6-4E7C-A146-EFF3C0A7CFC6Q35589974-9FD9919D-848B-4757-85C4-B24710D38318Q36021630-CCCF58C5-80B1-4A67-BF8F-FAD27BFBA12BQ36149174-81D9785F-6608-4825-AE8A-99C03EF4A97BQ36461774-6843A788-9284-43EA-8DDC-CB593DBC99D8Q36589468-4B26E88B-B9E5-43E0-AD5C-CBE225DD6915Q36709633-228EA2D2-713A-4BA4-9F6B-4CC1013B238EQ36824477-417D225E-C5FE-4E73-98A7-B97F705AE99CQ37028407-E4AD0F4A-2F00-45B9-AFBA-56F8E461EA5AQ37066471-21C97215-C05B-43C0-9A3D-3A88F79F20A3Q37087286-5B79A6A8-A1F7-4D6E-96FA-426C760E9D23Q37166144-72533FD6-8EF3-4331-95E9-FD3FD2DC45A6Q37311980-C886DFDC-71F9-44CD-A3F4-D4C77E52E953Q37392393-3ED849B3-749C-47CF-AA5C-2128F7D925D7Q37766239-3DF6CE33-0EED-4033-BFF0-CF863593ED1FQ37855928-C88AB529-D9FF-4786-A081-65498B37EC1AQ38837127-0757DA80-5E38-41A9-9D74-9396309AF27BQ38842262-D02E9448-932B-4301-910E-7C181104EB3CQ39031469-5497FA1B-199B-436B-A9E9-7FBD066AF42BQ40010571-56EB52AF-BE3A-4549-B10D-BF0B1A43F9C8Q40280096-7E7A6487-500A-4A92-BC6F-F522F61071DDQ41664978-7F4CA361-82A3-4F1E-8584-5AD658ADE9ADQ42167185-3671E126-D27D-4CC4-BCD6-430F3047CB64Q43265597-237EFDF2-8466-4081-8DF3-CB379D0F0D35Q44332439-E9195F77-A088-4BE8-8553-0C0E3CF4706CQ44334674-361EF550-FEC2-44CB-BCE5-8B84B1EC9928Q44348113-A35CBFCF-C797-45F7-9941-E51D46615C12Q46320227-37D6171E-802F-481F-9D2F-272C612DE532Q46444628-A1C5A3F9-DE24-480F-995B-E9250D08FEAD
P2860
Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Evidence about the use of nalt ...... n the treatment of alcoholism.
@ast
Evidence about the use of nalt ...... n the treatment of alcoholism.
@en
type
label
Evidence about the use of nalt ...... n the treatment of alcoholism.
@ast
Evidence about the use of nalt ...... n the treatment of alcoholism.
@en
prefLabel
Evidence about the use of nalt ...... n the treatment of alcoholism.
@ast
Evidence about the use of nalt ...... n the treatment of alcoholism.
@en
P356
P1476
Evidence about the use of nalt ...... n the treatment of alcoholism.
@en
P2093
Sinclair JD
P356
10.1093/ALCALC/36.1.2
P577
2001-01-01T00:00:00Z